Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ClinicalTrials.Gov Lists 22 Lilly Studies; Response To FDA Deadline Is Mixed

Executive Summary

Lilly has 22 open protocols listed on the National Library of Medicine's ClinicalTrials.gov website

You may also be interested in...



ClinicalTrials.gov Postings By Industry Increase, But Still Appear Incomplete

The ClinicalTrials.gov database includes over 650 open protocols sponsored by the pharmaceutical industry as of June 17

ClinicalTrials.gov Postings By Industry Increase, But Still Appear Incomplete

The ClinicalTrials.gov database includes over 650 open protocols sponsored by the pharmaceutical industry as of June 17

Lilly/Isis Affinitak Pivotal Trial Fails: Future Rests On Second Phase III Study

Lilly will await results from a second Phase III Affinitak study before making a final decision regarding its future role in developing Isis' antisense agent for non-small cell lung cancer

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS039931

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel